The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether dental examinations at three-month intervals and preventive treatments changes MRONJ (incidence proportion) compared with standard care (very low certainty).
Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).